Drug intelligence / Profile preview

erlotinib + capmatinib + enfortumab vedotin

Development stage: Unknown
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This is a combination of three distinct cancer medications: - **Erlotinib (Tarceva)**: A tyrosine kinase inhibitor that works by blocking the epidermal growth factor receptor (EGFR), which is involved in cancer cell growth and survival. It is used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations and pancreatic cancer. - **Capmatinib**: A targeted therapy for NSCLC. - **Enfortumab vedotin (Padcev)**: An antibody-drug conjugate used in cancer treatment.

Brand names: Tarceva + capmatinib + Padcev

Targets

PVRL4 (Nectin cell adhesion molecule 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on erlotinib + capmatinib + enfortumab vedotin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + capmatinib + enfortumab vedotin.

Explore the full profile